Asset profile

metformin · Glucophage

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — Type 2 Diabetes

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Upcoming events

(25 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (6)
October 2026 (3)
Phase 3Type 2 DiabetesActive not recruiting
Est. primary completion 2026-10-01 · NCT06257966 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Type 2 DiabetesActive not recruiting
Est. primary completion 2026-10-18 · NCT07033585 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Type 2 DiabetesActive not recruiting
Est. primary completion 2026-10-30 · NCT07026968 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (1)
Phase 2/3Parkinson DiseaseRecruiting
Est. primary completion 2026-11-20 · NCT07229651 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (2)
Phase 2Inflammatory Bowel DiseasesRecruiting
Est. primary completion 2026-12 · NCT05574387 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2026-12 · NCT07093476 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (10)
January 2027 (1)
Phase 2Multiple SclerosisRecruiting
Est. primary completion 2027-01-01 · NCT06463743 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (2)
Phase 2Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary-progressive Multiple SclerosisActive not recruiting
Est. primary completion 2027-02-28 · NCT05893225 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Intermittent ClaudicationRecruiting
Est. primary completion 2027-02-28 · NCT05132439 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (2)
Phase 1/2Multiple Sclerosis (MS)Recruiting
Est. primary completion 2027-03 · NCT04121468 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Cirrhosis, Portal Hypertension Related to CirrhosisRecruiting
Est. primary completion 2027-03-30 · NCT06687265 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (1)
Phase 1/2Heart Failure, Left Ventricular Assist DeviceNot yet recruiting
Est. primary completion 2027-07 · NCT07666698 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)
Phase 2Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-09-01 · NCT07139405 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (3)
Phase 2GlaucomaRecruiting
Est. primary completion 2027-12-31 · NCT05426044 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3SchizophreniaRecruiting
Est. primary completion 2027-12-31 · NCT07045142 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3PreeclampsiaRecruiting
Est. primary completion 2027-12-31 · NCT06033131 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (2)
February 2028 (1)
Phase 1/2ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal DegenerationActive not recruiting
Est. primary completion 2028-02-02 · NCT04545736 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)
Phase 3Pre-Eclampsia Onset Less Than 37 Weeks, Pre-Eclampsia, Pre-Eclampsia; Complicating Pregnancy, Pre-Eclampsia as Antepartum Condition …Not yet recruiting
Est. primary completion 2028-04 · NCT06452498 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (2)
May 2029 (1)
Phase 3COPDNot yet recruiting
Est. primary completion 2029-05-01 · NCT06999343 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)
Phase 3Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2029-06-16 · NCT06763328 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (3)
July 2030 (1)
Phase 1/2Breast Cancer, Solid Tumors, AdultRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (1)
Phase 1/2Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)
March 2031 (1)
Phase 3Alzheimer's Disease (AD), Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer Disease DementiaRecruiting
Est. primary completion 2031-03 · NCT07724132 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)
April 2032 (1)
Phase 2Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma …Recruiting
Est. primary completion 2032-04-30 · NCT04114136 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.